Challenges in the Detection of SARS-CoV-2: Evolution of the Lateral Flow Immunoassay as a Valuable Tool for Viral Diagnosis

Nayeli Shantal Castrejón-Jiménez; Blanca Estela García-Pérez; Nydia Edith Reyes-Rodríguez; Vicente Vega-Sánchez; Víctor Manuel Martínez-Juárez; Juan Carlos Hernández-González

doi:10.3390/bios12090728

Challenges in the Detection of SARS-CoV-2: Evolution of the Lateral Flow Immunoassay as a Valuable Tool for Viral Diagnosis

Nayeli Shantal Castrejón-Jiménez, Blanca Estela García-Pérez, Nydia Edith Reyes-Rodríguez, Vicente Vega-Sánchez, Víctor Manuel Martínez-Juárez, Juan Carlos Hernández-González

Escuela Nacional de Ciencias Biológicas (ENCB)

Research output: Contribution to journal › Review article › peer-review

13 Scopus citations

Abstract

SARS-CoV-2 is an emerging infectious disease of zoonotic origin that caused the coronavirus disease in late 2019 and triggered a pandemic that has severely affected human health and caused millions of deaths. Early and massive diagnosis of SARS-CoV-2 infected patients is the key to preventing the spread of the virus and controlling the outbreak. Lateral flow immunoassays (LFIA) are the simplest biosensors. These devices are clinical diagnostic tools that can detect various analytes, including viruses and antibodies, with high sensitivity and specificity. This review summarizes the advantages, limitations, and evolution of LFIA during the SARS-CoV-2 pandemic and the challenges of improving these diagnostic devices.

Original language	English
Article number	728
Journal	Biosensors
Volume	12
Issue number	9
DOIs	https://doi.org/10.3390/bios12090728
State	Published - Sep 2022

Keywords

COVID-19
SARS-CoV-2
antibodies
biosensors
diagnosis
lateral flow immunoassay

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/bios12090728

Cite this

@article{6f01125caf2748f7b667eb576f7ef87b,

title = "Challenges in the Detection of SARS-CoV-2: Evolution of the Lateral Flow Immunoassay as a Valuable Tool for Viral Diagnosis",

abstract = "SARS-CoV-2 is an emerging infectious disease of zoonotic origin that caused the coronavirus disease in late 2019 and triggered a pandemic that has severely affected human health and caused millions of deaths. Early and massive diagnosis of SARS-CoV-2 infected patients is the key to preventing the spread of the virus and controlling the outbreak. Lateral flow immunoassays (LFIA) are the simplest biosensors. These devices are clinical diagnostic tools that can detect various analytes, including viruses and antibodies, with high sensitivity and specificity. This review summarizes the advantages, limitations, and evolution of LFIA during the SARS-CoV-2 pandemic and the challenges of improving these diagnostic devices.",

keywords = "COVID-19, SARS-CoV-2, antibodies, biosensors, diagnosis, lateral flow immunoassay",

author = "Castrej{\'o}n-Jim{\'e}nez, {Nayeli Shantal} and Garc{\'i}a-P{\'e}rez, {Blanca Estela} and Reyes-Rodr{\'i}guez, {Nydia Edith} and Vicente Vega-S{\'a}nchez and Mart{\'i}nez-Ju{\'a}rez, {V{\'i}ctor Manuel} and Hern{\'a}ndez-Gonz{\'a}lez, {Juan Carlos}",

note = "Publisher Copyright: {\textcopyright} 2022 by the authors.",

year = "2022",

month = sep,

doi = "10.3390/bios12090728",

language = "Ingl{\'e}s",

volume = "12",

journal = "Biosensors",

issn = "2079-6374",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "9",

}

TY - JOUR

T1 - Challenges in the Detection of SARS-CoV-2

T2 - Evolution of the Lateral Flow Immunoassay as a Valuable Tool for Viral Diagnosis

AU - Castrejón-Jiménez, Nayeli Shantal

AU - García-Pérez, Blanca Estela

AU - Reyes-Rodríguez, Nydia Edith

AU - Vega-Sánchez, Vicente

AU - Martínez-Juárez, Víctor Manuel

AU - Hernández-González, Juan Carlos

PY - 2022/9

Y1 - 2022/9

N2 - SARS-CoV-2 is an emerging infectious disease of zoonotic origin that caused the coronavirus disease in late 2019 and triggered a pandemic that has severely affected human health and caused millions of deaths. Early and massive diagnosis of SARS-CoV-2 infected patients is the key to preventing the spread of the virus and controlling the outbreak. Lateral flow immunoassays (LFIA) are the simplest biosensors. These devices are clinical diagnostic tools that can detect various analytes, including viruses and antibodies, with high sensitivity and specificity. This review summarizes the advantages, limitations, and evolution of LFIA during the SARS-CoV-2 pandemic and the challenges of improving these diagnostic devices.

AB - SARS-CoV-2 is an emerging infectious disease of zoonotic origin that caused the coronavirus disease in late 2019 and triggered a pandemic that has severely affected human health and caused millions of deaths. Early and massive diagnosis of SARS-CoV-2 infected patients is the key to preventing the spread of the virus and controlling the outbreak. Lateral flow immunoassays (LFIA) are the simplest biosensors. These devices are clinical diagnostic tools that can detect various analytes, including viruses and antibodies, with high sensitivity and specificity. This review summarizes the advantages, limitations, and evolution of LFIA during the SARS-CoV-2 pandemic and the challenges of improving these diagnostic devices.

KW - COVID-19

KW - SARS-CoV-2

KW - antibodies

KW - biosensors

KW - diagnosis

KW - lateral flow immunoassay

UR - http://www.scopus.com/inward/record.url?scp=85138336471&partnerID=8YFLogxK

U2 - 10.3390/bios12090728

DO - 10.3390/bios12090728

M3 - Artículo de revisión

C2 - 36140114

AN - SCOPUS:85138336471

SN - 2079-6374

VL - 12

JO - Biosensors

JF - Biosensors

IS - 9

M1 - 728

ER -

Challenges in the Detection of SARS-CoV-2: Evolution of the Lateral Flow Immunoassay as a Valuable Tool for Viral Diagnosis

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this